A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Design to Evaluate the Efficacy and Safety of Teriflunomide (HMR 1726D) in Reducing the Frequency of Relapses and Delaying the Accumulation of Physical Disability in Subjects with Multiple Sclerosis with Relapses, Sanofi-Aventis.